125 related articles for article (PubMed ID: 33805971)
1. Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
Koerber SA; Boesch J; Kratochwil C; Schlampp I; Ristau J; Winter E; Zschaebitz S; Hofer L; Herfarth K; Kopka K; Holland-Letz T; Jaeger D; Hohenfellner M; Haberkorn U; Debus J; Giesel FL
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805971
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
4.
Wang Z; Zheng A; Li Y; Dong W; Liu X; Yuan W; Gao F; Duan X
Front Oncol; 2021; 11():759053. PubMed ID: 34778079
[TBL] [Abstract][Full Text] [Related]
5. Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
Rogasch JM; Cash H; Zschaeck S; Elezkurtaj S; Brenner W; Hamm B; Makowski M; Amthauer H; Furth C; Baur ADJ
Prostate; 2018 Jul; ():. PubMed ID: 29978529
[TBL] [Abstract][Full Text] [Related]
6. The value of
Hong JJ; Liu BL; Wang ZQ; Tang K; Ji XW; Yin WW; Lin J; Zheng XW
EJNMMI Res; 2020 Nov; 10(1):138. PubMed ID: 33169183
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
8. The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer.
Erdoğan M; Özkan EE; Öztürk SA; Yıldız M; Şengül SS
Mol Imaging Radionucl Ther; 2020 Oct; 29(3):98-104. PubMed ID: 33094572
[TBL] [Abstract][Full Text] [Related]
9.
Zhou S; Liu T; Zhu Z; Zhang L; Qian S; Fu H; Cao Q; Kang J
Front Oncol; 2022; 12():800904. PubMed ID: 35186741
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
11. The
Wang Z; Zheng A; Li Y; Gao J; Dong W; Li Y; Duan X
Front Oncol; 2022; 12():935979. PubMed ID: 36091136
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Different Tumor Delineation Approaches for
Mittlmeier LM; Brendel M; Beyer L; Albert NL; Todica A; Zacherl MJ; Wenter V; Herlemann A; Kretschmer A; Ledderose ST; Schmidt-Hegemann NS; Kunz WG; Ricke J; Bartenstein P; Ilhan H; Unterrainer M
Front Oncol; 2021; 11():663631. PubMed ID: 34094956
[TBL] [Abstract][Full Text] [Related]
13.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
15. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
16. Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
Domachevsky L; Goldberg N; Bernstine H; Nidam M; Groshar D
Eur Radiol; 2018 Dec; 28(12):5275-5283. PubMed ID: 29846803
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
18. Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease.
Yechiel Y; Orr Y; Gurevich K; Gill R; Keidar Z
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831365
[TBL] [Abstract][Full Text] [Related]
19.
Sachpekidis C; Bäumer P; Kopka K; Hadaschik BA; Hohenfellner M; Kopp-Schneider A; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of [
Paymani Z; Rohringer T; Vali R; Loidl W; Alemohammad N; Geinitz H; Langsteger W; Beheshti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
